AI-generated analysis. Always verify with the original filing.
Contineum Therapeutics, Inc. reported Q4 2025 financial results with net loss of $15.2 million and cash of $262.9 million as of December 31, 2025, sufficient into mid-2029. The company amended its Sales Agreement with Leerink Partners to increase the at-the-market offering capacity to $100 million and initiated dosing in the PROPEL-IPF Phase 2 trial for PIPE-791 in IPF patients.
Event Type
Disclosure
Mandatory
Variant
8-K
(including Exhibit 99.1) hereto is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 19
Other Events. As previously reported, on May 14, 2025, the Company entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (“Leerink Pa
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Amendment No. 1 to Sales Agreement, dated March 5, 2026, by and between the Company
| Metric | Value | Basis |
|---|---|---|
| Research and development expenses | $12.8K | GAAP |
| General and administrative expenses | $4.4K | GAAP |
| Net loss | $-15.2K | GAAP |
| Net loss per share, basic and diluted | $-0.49 | GAAP |
Material Agreement